Tevogen Bio (NASDAQ:TVGN) Shares Down 8.9% – Time to Sell?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN)’s stock price was down 8.9% during mid-day trading on Tuesday . The stock traded as low as $1.36 and last traded at $1.53. Approximately 5,120,275 shares traded hands during trading, a decline of 6% from the average daily volume of 5,419,914 shares. The stock had previously closed at $1.68.

Tevogen Bio Trading Down 8.9 %

The company has a fifty day simple moving average of $1.21 and a 200-day simple moving average of $1.01.

Hedge Funds Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. China Universal Asset Management Co. Ltd. acquired a new stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 37,117 shares of the company’s stock, valued at approximately $38,000.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.